Business & Finance
Viva Biotech adds to production of oral COVID-19 drug molnupiravir in the joint fight against COVID-19
21 March 2022 -

Biotech company Viva Biotech Holdings (Stock Code:1873.HK) revealed on Friday that it is committed to the production of oral COVID-19 drugs and virus test in fight against the COVID-19 pandemic under the January 2022 Medicines Patent Pool (MPP) agreement.

Langhua Pharmaceutical, a subsidiary of Viva biotech holdings, reportedly signed an agreement with MPP for the manufacturing of the oral COVID-19 antiviral medication molnupiravir for the supply in 105 low-and-middle-income countries (LMICs).

As part of the agreement with MPP, about five companies will focus on producing the raw ingredients, 13 companies will produce both raw ingredient and the finished drug and nine companies will produce the finished drug.

Molnupiravir (MK-4482 and EIDD-2801) is an investigational, orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2 . The data from the Phase 3 MOVe-OUT demonstrated that early treatment with molnupiravir significantly reduced the risk of hospitalization or death in high risk, unvaccinated adults with COVID-19.

On 2 March 2022, Viva BioInnovator's Xlement received the notice of passing from the Ministry of Science and Technology of the People´s Republic of China for its project "R&D and Mass Production of NanoSPR COVID-19 Particle Test Kit", which is one of the key projects of the "Public Safety Risk Prevention and Control and Emergency Response Technology and Equipment" programme.